EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. | Semantic Scholar
Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie, - ppt download
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | NEJM
Dapagliflozin Benefits Patients with Mildly Reduced and Preserved Ejection Fraction | DAIC
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Peter Carson and Barry Massie Executive Committee M. Komajda, R. McKelvie, J. McMurray, - ppt download
Abstract 16784: Under-Enrollment of Real-World Heart Failure With Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials | Circulation
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine – the PRESERVE Trial | Cardiology Now
Will PRESERVE preserve the contrast AKI status quo? — NephJC
Design for the EMPEROR-Preserved Trial. | Download Scientific Diagram
EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF | tctmd.com
Diagram of the stepwise evaluation of endpoints in the EMPEROR-Reduced... | Download Scientific Diagram
PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction) | JACC: Heart Failure
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease | Stroke
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | NEJM
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction – Visualmed
Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Elsevier e-Prints
![PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3092ad4f375a1465b7d1d3a99b6ec0e96ba95eef/5-Figure1-1.png "PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar")
PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial - Anker - 2020 - European Journal of Heart Failure - Wiley Online Library
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
